BiondVax Pharmaceuticals Ltd (NYSE:BVXV) announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug. The study…
COVID-19 illness was virtually prevented in hamsters administered BiondVax’s inhaled NanoAb and infected three hours later with SARS-CoV-2
Data further strengthens value proposition of BiondVax’s
Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) shares are trading lower by 58.60% to $3.64 during Friday's session after the company priced its 1.6 million unit offering at $5 per unit.